Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minfeng Chen

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Nature Metabolism|September 4, 2023
ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapyChenran Wang, Maohua Huang, Yuning Lin, et al.
The Journal of Clinical Investigation|January 31, 2023
Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis modelsMing Qi, Shuran Fan, Maohua Huang, et al.
The Journal of Clinical Investigation|August 29, 2017
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agentsMinfeng Chen, Xueping Lei, Changzheng Shi, et al.
The Journal of Clinical Investigation|August 11, 2022
Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis modelsMing Qi, Shuran Fan, Maohua Huang, et al.
Journal of Medical Genetics|April 3, 2023
Validation and depth evaluation of low-pass genome sequencing in prenatal diagnosis using 387 amniotic fluid samplesYeqing Qian, Yan Sun, Xueqin Guo, et al.
Nature Communications|August 2, 2025
Pericytes promote metastasis by regulating tumor local vascular tone and hemodynamicsXiaobo Li, Sishan Yan, Xiaoyu Wu, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Cell Reports. Medicine|October 20, 2022
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective studyJiao Hu, Jinbo Chen, Zhenyu Ou, et al.
Gut|July 23, 2025
Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasisSheng Wang, Geni Ye, Xiaoling Xu, et al.
Clinical Genitourinary Cancer|May 10, 2025
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell CarcinomaCheoklong Ng, Cheng Peng, Shangqian Wang, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Nature Metabolism|September 4, 2023
ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapyChenran Wang, Maohua Huang, Yuning Lin, et al.
The Journal of Clinical Investigation|January 31, 2023
Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis modelsMing Qi, Shuran Fan, Maohua Huang, et al.
The Journal of Clinical Investigation|August 29, 2017
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agentsMinfeng Chen, Xueping Lei, Changzheng Shi, et al.
The Journal of Clinical Investigation|August 11, 2022
Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis modelsMing Qi, Shuran Fan, Maohua Huang, et al.
Journal of Medical Genetics|April 3, 2023
Validation and depth evaluation of low-pass genome sequencing in prenatal diagnosis using 387 amniotic fluid samplesYeqing Qian, Yan Sun, Xueqin Guo, et al.
Nature Communications|August 2, 2025
Pericytes promote metastasis by regulating tumor local vascular tone and hemodynamicsXiaobo Li, Sishan Yan, Xiaoyu Wu, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Cell Reports. Medicine|October 20, 2022
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective studyJiao Hu, Jinbo Chen, Zhenyu Ou, et al.
Gut|July 23, 2025
Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasisSheng Wang, Geni Ye, Xiaoling Xu, et al.
Clinical Genitourinary Cancer|May 10, 2025
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell CarcinomaCheoklong Ng, Cheng Peng, Shangqian Wang, et al.
Pageof 21